Document:

First Amendment to Employment Agreement

 Exhibit 10.30 
 FIRST AMENDMENT TO EMPLOYMENT AGREEMENT 
 This First Amendment to Employment Agreement (this
“Amendment”) is made and entered into effective as of December 24, 2008, by WALLACE D. RUIZ (“Executive”) and SRI/SURGICAL EXPRESS, INC., a Florida corporation (the “Company”).

 BACKGROUND 
 Executive and Company entered into an Employment Agreement dated as of July 1, 2005 (the “Employment Agreement”). Executive and Company desire to amend the Employment Agreement on the terms and conditions set forth
below in order to bring the Employment Agreement into compliance with Section 409A of the Internal Revenue Code of 1986, as amended (“Section 409A”). 
 OPERATIVE TERMS 
 In consideration of the respective agreements of the parties contained in
this Amendment and for other good and valuable consideration, the parties agree to amend the Employment Agreement as follows: 
 1. The
definitions of “Involuntary Termination” and “Severance Date” in Section 1 of the Employment Agreement are amended and restated to read as follows: 
 “Involuntary Termination” means the termination of Executive by the Company for any reason other than for Cause, death, or Disability
that constitutes an “involuntary separation from service” within the meaning of Treasury Regulations Section 1.409A-1(n)(1). To the extent necessary to comply with Section 409A, references to “termination of
employment,” “separation from service” or variations thereof in this Agreement shall mean the Executive’s “separation from service” from the Company within the meaning of Section 409A(a)(2)(A)(i) and the default
rules of Treasury Regulations Section 1.409A-1(h). 
 “Severance Date” means the effective date of Executive’s
separation from service from the Company by reason of an Involuntary Termination. To the extent necessary to comply with Section 409A, references to the “date of employment termination” or variations thereof in this Agreement shall
mean the Severance Date. 
 2. Section 4(a)(ii) of the Employment Agreement is amended by inserting the following sentences at the end
thereof: 
 To receive an annual bonus for any calendar year, Executive must remain employed with the Company until the time of payment. All
annual bonuses shall be paid to Executive on or after January 1 and on or before March 31 of the year immediately following the year to which the bonus relates. 

 3. Section 4(e) of the Employment Agreement is amended by inserting the following sentence at the
end thereof: 
 A termination of employment at the election of the Executive shall be treated as an Involuntary Termination by reason of this
Section 4(e) only if Executive voluntarily separates from service from the Company within ninety (90) days following the end of the 90-day period during which D&O Coverage is not maintained. The foregoing good reason provision
is intended to qualify under Treasury Regulations Section 1.409A-1(n)(2) to be treated as an involuntary separation from service, and shall be interpreted and administered consistently therewith. 
 4. The penultimate sentence of Section 8(b)(i) of the Employment Agreement is amended and restated to read as follows: 
 In addition, the Company shall (A) continue to pay to the Executive his Annual Salary as scheduled for a period of nine (9) months following
the Severance Date, as his sole severance compensation benefit; provided that such payments will be paid in accordance with the Company’s payroll dates in effect on the Severance Date, and such payment dates will not be affected by any
subsequent change in the Company’s payroll practices, and (B) provided that Executive is eligible for and timely elects continuation of his health insurance benefits pursuant to COBRA, for a period of nine (9) months following the
Severance Date, the Company shall pay COBRA premiums in order for Executive to maintain medical insurance coverage at the level in effect on the Severance Date; provided, however, that the Company’s obligation to pay
Executive’s COBRA premiums will cease immediately in the event Executive becomes eligible for group health insurance during such nine (9) month period, and Executive agrees to promptly notify the Company if he becomes eligible to be
covered by group health insurance during such period. 
 5. Section 8(b)(ii) of the Employment Agreement is amended by inserting the
following sentence at the end thereof: 
 If the Executive has not executed and delivered the release referenced in the first sentence of
this Section 8(b)(ii) with all periods for revocation thereof expired as of the date that is sixty (60) days after the Severance Date (“Required Release Date”), the Executive shall forfeit the right to receive the
foregoing severance compensation. Any severance compensation that is not deferred compensation within the meaning of Section 409A shall commence upon the second payroll date following the first date on which the release is executed and
delivered with all periods for revocation thereof expired (the “Release Effective Date”), and continue for the remaining term of the nine month severance period after the Severance Date; provided that such first payment shall
include all such amounts that otherwise would have been paid prior to the Release Effective Date had the severance compensation commenced on the first payroll date following the Severance Date. Subject to Section 8(b)(iii), payments of
severance compensation that constitute deferred compensation within the meaning of Section 409A shall commence on the second payroll date after the Required Release Date (regardless of when the Release Effective Date occurs); and continue for
the remaining term of the nine month severance period after the Severance Date; provided that such first payment shall include all such amounts that otherwise would have been paid prior to the Required Release Date had the severance
compensation commenced on the first payroll date following the Severance Date. 
  

 2 

 6. The Employment Agreement is amended by adding the following as new Section 8(b)(iii) thereof:

 (iii) Specified Employee. Notwithstanding anything to the contrary in this Agreement, if Executive is a “specified
employee” (as determined by the Company under Section 409A) on the Severance Date, to the extent that Executive is entitled to receive any benefit or payment upon such separation from service under this Agreement that constitutes deferred
compensation within the meaning of Section 409A before the date that is six (6) months after the Severance Date, such benefits or payments shall not be provided or paid to Executive on the date otherwise required to be provided or paid.
Instead, all such amounts shall be accumulated and paid in a single lump sum to Executive on the first business day after the date that is six (6) months after the Severance Date (or, if earlier, within fifteen (15) days following
Executive’s date of death). All benefits or payments otherwise required to be provided or paid on or after the date that is six (6) months after the Severance Date shall not be affected by this Section 8(b)(iii). Prior to the
imposition of the six month delay as set forth in this Section 8(b)(iii), it is intended that (i) each installment under this Agreement be regarded as a separate “payment” for purposes of Section 409A, and
(ii) all benefits or payments provided under this Agreement satisfy, to the greatest extent possible, the exemptions from the application of Section 409A provided under Treasury Regulations Sections 1.409A-1(b)(4) (short-term
deferral) or 1.409A-1(b)(9) (certain separation pay plans). This Section 8(b)(iii) is intended to comply with the requirements of Section 409A(a)(2)(B)(i) of the Code. 
 7. The Employment Agreement is amended by adding the following as new Section 13 thereof: 
 13. Tax Matters. 
 (a) Reimbursement and In-Kind Benefits. To the extent this Agreement provides for reimbursements of expenses incurred by Executive or in-kind benefits the provision of which are not exempt from the requirements of Section 409A,
the following terms apply with respect to such reimbursements or benefits: (1) the reimbursement of expenses or provision of in-kind benefits will be made or provided only during the term of employment hereunder, or other period of time
specifically provided herein; (2) the amount of expenses eligible for reimbursement, or in-kind benefits provided, during a taxable year will not affect the expenses eligible for reimbursement, or in-kind benefits to be provided, in any other
taxable year; (3) all reimbursements will be made upon Executive’s request in accordance with the Company’s normal policies but no later than the last day of the calendar year immediately following the calendar year in which the
expense was incurred; and (4) the right to the reimbursement or the in-kind benefit will not be subject to liquidation or exchange for another benefit. 
 (b) Section 409A; Liability for Taxes. The parties intend for this Agreement to conform in all respects to the requirements
under Section 409A or an exemption thereto. Accordingly, the parties intend for this Agreement to be interpreted, construed, administered and applied in a manner as shall meet and comply with the requirements of Section 409A or an
exemption thereto. Notwithstanding any other provision of this Agreement, none of the Company, its subsidiaries or affiliates or any individual acting as a director, officer, employee, agent or other representative of the Company or a subsidiary or
affiliate shall be liable to Executive or any other person for any claim, loss, liability or expense arising out of any interest, penalties or additional taxes due by Executive or any other person as a result of this Agreement or the administration
thereof not satisfying any of the requirements of Section 409A. 
  

 3 

 8. Except as expressly amended by this Amendment, all other terms and conditions of the Employment
Agreement shall remain in full force and effect. 
 9. The parties may execute this Amendment in counterparts. Each executed counterpart will
constitute an original document, and all executed counterparts, together, will constitute the same agreement. 
 [Signature Page Follows]

  

 4 

 SIGNATURE PAGE TO 
 FIRST AMENDMENT TO EMPLOYMENT AGREEMENT 
 IN WITNESS WHEREOF, the Company and Executive have
executed this Amendment effective as of the date first set forth above. 
  

									
	WITNESSES:	 		 	 SRI/SURGICAL EXPRESS, INC.,
 a Florida
corporation

				
	/s/ Ray Reilly	 		 	By:	 	/s/ Gerald Woodard
		 		 		 	Name:	 	Gerald Woodard
	 	 		 	Title:	 	CEO
			
	WITNESSES:	 		 	“EXECUTIVE”
			
	/s/ Ray Reilly	 		 	/s/ Wallace D. Ruiz
		 		 		 	WALLACE D. RUIZ
			
	 	 		 	

  

 5Supply and Co-Marketing Agreement

 Exhibit 10.31 
 PORTIONS OF THIS EXHIBIT MARKED “[* * *]” HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT PURSUANT TO RULE 24b-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND THE OMITTED
PORTIONS HAVE BEEN FILED SEPARATELY IN PAPER FORM WITH THE SECURITIES AND EXCHANGE COMMISSION. 
 SUPPLY AND CO-MARKETING AGREEMENT

 This Supply and Co-Marketing Agreement is effective as of November 26, 2008 (“Effective Date”), between Cardinal
Health 200, Inc., a Delaware corporation (“Cardinal Health”), and SRI/Surgical Express, Inc., a Florida corporation (“SRI”) (Cardinal Health and SRI are collectively referred to in this Agreement as the
“parties”). 
 BACKGROUND 
 Cardinal Health is a manufacturer and distributor of healthcare products and disposable kitting solutions. SRI provides reusable and disposable kitting solutions to healthcare providers. Cardinal Health desires to
appoint SRI as a distributor of the Products (as defined below), and SRI desires to accept such appointment. In addition, the parties desire that SRI consolidate and package the Hybrid Kits (as defined below) to be jointly developed, produced and
marketed by the parties. 
 OPERATIVE TERMS 
 Cardinal Health and SRI agree as follows: 
  

	1.	DEFINITIONS 

 “Billing Party” has
the meaning set forth in Section 3.5. 
 “Cardinal Health Components” means the disposable surgical component products
provided by Cardinal Health that comprise the disposable sub-assemblies used in the Hybrid Kits. 
 “Cardinal Health
Presource/Convertors Legacy Customer” means any customer of Cardinal Health as of the date of this Agreement. 
 “Change of
Control” means the occurrence of any of the following: 
 (i) any person or entity, or group thereof acting in concert (a
“Person”), being or becoming the “beneficial owner” (as such term is defined in Securities and Exchange Commission (“SEC”) Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the
“Exchange Act”)), directly or indirectly, of securities of SRI which, together with securities previously owned, confer upon such Person or group the combined voting power, on any matters brought to a vote of shareholders, of
fifty-one percent (51%) or more of the then outstanding shares of voting securities of SRI; 

 (ii) the direct or indirect sale, lease, assignment, conveyance, transfer or other disposition of assets
of SRI or any of its subsidiary or subsidiaries, in a transaction or series of transactions, if the aggregate consideration received or to be received by SRI or any such subsidiary in connection with such sale, lease, assignment, conveyance,
transfer or other disposition is greater than fifty-one percent (51%) of the book value, determined by SRI in accordance with generally accepted accounting principles, of SRI’s assets determined on a consolidated basis immediately before
such transaction or the first of such transactions; 
 (iii) the merger, consolidation, share exchange or reorganization of SRI (or one or
more direct or indirect subsidiaries of SRI) as a result of which the holders of all of the shares of capital stock of SRI as a group would receive less than fifty-one percent (51%) of the combined voting power of the voting securities of SRI
or such surviving or resulting entity or any parent thereof immediately after such merger, consolidation, share exchange or reorganization; 
 (iv) the adoption of a plan relating to SRI’s liquidation or the approval of the dissolution of SRI; 
 (v) the commencement
(within the meaning of SEC Rule 13e-4 under the Exchange Act) of a tender or exchange offer which, if successful, would result in a Change of Control of SRI; or 
 (vi) the first day on which a majority of the members of SRI’s board of directors are not Continuing Directors. 
 “Competing Products” means “green” alternative or reusable products other than the Hybrid Kits and any disposable or reusable component products. 
 “Component Products” means the Cardinal Health Components and the SRI Components. 
 “Continuing Director” means, as of any date of determination, any member of SRI’s board of directors who (i) was a member of
such board of directors on the Effective Date or (ii) was nominated for election, elected or appoint to such board of directors with the approval of the majority of the Continuing Directors who were members of such board of directors at the
time of such nomination, election or appointment (either by a specific vote or by approval of SRI’s proxy statement in which such member was name a nominee for election as a director, without objection to such nomination). 
 “Customer Agreement” means an agreement between a Customer and SRI or Cardinal Health, as the case may be, to provide the Hybrid Program
to the Customer. 
  

 2 

 “Customers” means the hospitals, surgery centers and other customers that execute
Customer Agreements and participate in the Hybrid Program. 
 “Disposable Products” means the disposable products
manufactured, sourced or supplied by Cardinal Health that a SRI Legacy Customer desires to purchase from SRI, including without limitation all disposable products that are purchased by a SRI Legacy Customer as of the Effective Date and, in the case
of such disposable products that are not manufactured, sourced or supplied by Cardinal Health, all comparable products manufactured, sourced or supplied by Cardinal Health. 
 “FDA” means the United States Food and Drug Administration. 
 “Hybrid Kits” means hybrid kits consisting of disposable and reusable components that the parties jointly develop. 
 “Hybrid Program” means the assembly, delivery to Customers and retrieval from Customers of the Hybrid Kits and the reprocessing of the
SRI Components. 
 “Intellectual Property” has the meaning set forth in Section 4.1. 
 “Management Committee” has the meaning set forth in Section 9.2. 
 “Margin Percentage” has the meaning set forth in Section 2.3. 
 “Measurement Date” means the second anniversary of the Effective Date and each anniversary thereafter. 
 “Non-Billing Party” has the meaning set forth in Section 3.5. 
 “Operating Committee” has the meaning set forth in Section 9.3. 
 “Products” means the Component Products and the Disposable Products. 
 “Recall” has the meaning set forth in Section 2.9(f). 
 “Restricted Information” has the meaning set forth in Section 8. 
 “SRI Components” means the reusable surgical component products provided by SRI that comprise the reusable sub-assemblies used in the
Hybrid Kits. 
 “SRI Legacy Customer” means any customer of SRI as of the Effective Date. 
 “SRI Marks” has the meaning set forth in Section 9.6. 
  

 3 

 “SRI Services” means the delivery, retrieval and reprocessing and other services
provided by SRI under the Hybrid Program. 
 “Territory” means the United States. 
 “Total Revenues” means, for each annual period during the term of this Agreement, the amount equal to the gross revenues generated by
sales under the Hybrid Program, less the aggregate amount of product returns under the Hybrid Program, during that annual period. 
 “Total Revenue Target” means, for each annual period, an amount equal to one hundred and eight percent (108%) of the Total Revenues for the immediately prior annual period. 
  

	2.	DISPOSABLE PRODUCTS 

 2.1 Products Covered by
this Article. The products covered by this Article are the Disposable Products. There are no volume or purchase commitments of any kind under this Article. 
 2.2 Grant of Distributorship; Exclusive Supplier. Cardinal Health hereby appoints SRI as a non-exclusive distributor of the Disposable Products in the Territory and SRI accepts such grant for the term
and on the conditions stated in this Agreement. Subject to the following sentence, (a) during the term of this Agreement, SRI hereby appoints Cardinal Health as the exclusive supplier of the Disposable Products in the Territory and Cardinal
Health accepts such appointment and (b) SRI shall not purchase Disposable Products from any party other than Cardinal Health without Cardinal Health’s prior written consent. Notwithstanding the foregoing sentence, if on any Measurement
Date, the amount of Total Revenues for the annual period ending on the Measurement Date are less than the Total Revenue Target for such period, SRI may, upon prior written notice to Cardinal Health, elect that Cardinal Health shall be a
non-exclusive supplier of the Disposable Products for use in the Hybrid Kits and SRI shall be permitted to purchase Disposable Products for use in the Hybrid Kits from any party. For the avoidance of doubt, Cardinal Health shall, during the term of
this Agreement, remain SRI’s exclusive supplier of the Disposable Products for sale to the SRI Legacy Customers regardless of the amount of Total Revenues. If the failure to satisfy the Total Revenue Target is a result of unforeseeable and
extenuating circumstances (including significant market deterioration), SRI agrees that, prior to electing to purchase Disposable Products from any party other than Cardinal Health, SRI shall first discuss its election with the Management Committee.

 2.3 SRI Legacy Customer Pricing. 
 (a) The price for each SRI Legacy Customer Disposable Product ordered by SRI shall be an amount that results in the Margin Percentage
being equal to [* * *] percent ([* * *]%) for all orders made prior to the first anniversary of the date that Cardinal Health delivers the first Disposable Product to SRI pursuant to this Agreement and [* * *] percent ([* * *]%) thereafter. For
purposes of this Agreement, the “Margin  

  

 4 

 
Percentage” shall be the quotient of (i) the difference between (A) the price charged to SRI’s customer for such Disposable
Product (excluding any delivery or transportation fees charged to SRI customers) less (B) the price charged to SRI under this Agreement for such Disposable Product divided by (ii) the price charged to SRI’s customer for
such Disposable Product (excluding any delivery or transportation fees). For the avoidance of doubt, revenue and billing charges to SRI customers for SRI products, including without limitation reusable component products, instruments and service
offerings, shall be excluded from the calculation of the Margin Percentage. 
 (b) Terms of payment shall be net 45 days from
date of invoice. 
 2.4 Labeling. The Disposable Products shall be labeled with a co-branded label mutually agreed to by the
parties and substantially in the form attached hereto as Annex A. 
 2.5 Delivery; Risk of Loss. Title and risk of loss
or damage to the Disposable Products pass to SRI when the Disposable Products are unloaded at SRI’s place of delivery and accepted by SRI. Unless agreed to by SRI in advance, Cardinal Health shall not deliver any partial orders. In addition,
SRI may refuse to accept, and may return to Cardinal Health, freight collect, at Cardinal Health’s risk, any Disposable Products that are not ordered by SRI. 
 2.6 Nonconforming Products. SRI may reject delivery of Disposable Products up to 72 hours after delivery if such Disposable Products are nonconforming. If SRI properly rejects any Disposable Products as
nonconforming, Cardinal Health, at its sole cost and expense, as soon as practicable after the effective date of SRI’s notice of rejection, shall either (a) cause the rejected Disposable Products to conform or (b) deliver to SRI new
Disposable Products that conform to the order. Cardinal Health acknowledges that Disposable Products are also subject to acceptance or rejection by Customers, and will promptly following any Customer rejection, (i) cause the rejected Disposable
Products to conform or (ii) deliver to SRI new Disposable Products that conform to the order. 
 2.7 Inspection. With
respect to those Disposable Products manufactured by Cardinal Health, Cardinal Health shall permit SRI or its agents or representatives to inspect and observe finished Disposable Products in the process of manufacture, at any reasonable time during
Cardinal Health’s normal business hours, and shall provide adequate space and facilities necessary for SRI’s agents or representatives to conduct an inspection or observation upon reasonable advance notice to Cardinal Health. 

2.8 SRI’s Duties Regarding Disposable Products. With respect to the Disposable Products, SRI shall: 
 (a) Submit its order for Disposable Products via an electronic data interchange (EDI) or Cardinal Health’s Web-based ordering system,
such as www.Cardinal.com. 
 (b) Pay for such orders in accordance with the payment terms specified in Section 2.3.

  

 5 

 (c) Maintain complete and accurate records for such periods as may be required by
applicable law, of all the Disposable Products sold by it. 
 (d) Provide the staff it deems reasonably necessary to accept
orders from the SRI Legacy Customers for Disposable Products and to provide other customer service support. 
 (e) Provide
billing, collection and related administrative services for the Customers purchasing Disposable Products through the SRI channel. 
 (f) Reasonably assist Cardinal Health in carrying out any Recall at Cardinal Health’s request, cost and expense. 
 (g) Communicate all complaints to Cardinal Health on Disposable Products in a timely fashion. 
 (h) Make all claims
for any discrepancies in shipping, unpaid invoices, rebate requests, or any other discrepancy resulting in receivable discrepancy in writing within one (1) year of the date of the discrepancy. Cardinal Health shall not be obligated to make
payments for, or investigate claims which are dated more than one (1) year prior to SRI’s written claim or request for investigation. 
 (i) Accept and implement a Continuous Replenishment Process (“CRP”) with Cardinal Health on purchase orders for all Cardinal Health Component Products within sixty (60) days of the Effective
Date. If SRI does not implement an operational CRP process on Cardinal Health Component Products by the date set forth above and does not cure such failure within thirty (30) days after notice from Cardinal Health, then Cardinal Health may
charge SRI a handling fee of five percent (5%) on all orders of Cardinal Health Component Products by SRI until such time as the CRP process is in place. 
 (j) Use its reasonable efforts to report any shipping discrepancies within seventy-two (72) hours of delivery of the Cardinal Health
Component Products to Cardinal Health customer service representatives. 
 2.9 Cardinal Health’s Duties Regarding Disposable
Products. With respect to the Disposable Products, Cardinal Health shall: 
 (a) Timely ship all Disposable Products
F.O.B. destination to the SRI facilities designated by SRI in the applicable purchase order. 
 (b) Within five
(5) business days after the end of each month and receipt of customer purchase data from SRI, pay to SRI a tracing fee of [* * *]% of Cardinal Health’s gross revenues with respect to the Disposable Products and a prompt pay fee of [* * *]%
15, net 45. 
  

 6 

 (c) Maintain 98% Disposable Product Fill Rate (as defined below) for Disposable Products.
“Disposable Product Fill Rate” is defined as (i) the quantity of Disposable Products meeting the warranty requirements set forth in Section 4.1 actually shipped as of the delivery date set forth in SRI’s purchase
order, divided by (ii) the quantity of Disposable Products that should have been shipped in accordance with that purchase order. SRI will measure the Disposable Product Fill Rate on a quarterly basis with respect to all of the purchase
orders submitted by SRI to Cardinal Health for such calendar quarter. If Cardinal Health fails to meet the Disposable Product Fill Rate with respect to any calendar quarter and, after notice of such failure by SRI, fails to maintain the Disposable
Product Fill Rate for the immediately following calendar quarter, SRI may invoice and collect from Cardinal Health an amount equal to 10% of the value of the Disposable Product for each 1% the Disposable Product Fill Rate was below 98% with respect
to the purchase orders for any calendar month for which the Disposable Product Fill Rate was below 98%. SRI acknowledges that Cardinal Health’s ability to comply with the foregoing requirements depends on its timely receipt of accurate and
complete forecasts and ordering information from SRI via an electronic data interchange (EDI) or Cardinal Health’s Web-based ordering system, such as www.Cardinal.com. 
 (d) Take all necessary action to comply with applicable FDA and other federal, state and local requirements in connection with the
manufacture, sale, distribution and provision of the Disposable Products. These obligations include without limitation compliance with the applicable sections of the Quality System Regulation (21 C.F.R. Part 820). Each party shall possess a Quality
Assurance System that adheres to applicable laws, rules, and regulations, including without limitation the practices and regulations of the FDA (including without limitation the applicable sections of the current Quality System Regulations as
expressed in 21 C.F.R. Part 820 and Pre-Market Notification Procedures of 21 C.F.R. Part 807, Subpart E). 
 (e) Notify SRI
and the appropriate federal, state and local authorities of any customer complaints or other occurrences regarding the Disposable Products which are required to be so reported or that may render all or any of the Disposable Products in violation of
a law or regulation, evaluating all complaints and responding to SRI in writing on the resolution of any complaints from SRI or its customers. SRI and Cardinal Health shall provide each other with any information it receives regarding such
occurrences. Cardinal Health shall be responsible for evaluating all complaints and for responding to SRI in writing. 
 (f)
In the event that any defect in a Disposable Product or any regulatory or government action requires that all or part of a Disposable Product be recalled, destroyed, withheld from the market, or subjected to field corrective action (a
“Recall”), Cardinal Health shall immediately notify SRI of the same and bear the entire responsibility of the Recall, at no cost to SRI, and shall reimburse SRI for all reasonable and direct costs associated with all Recalls, except
those Recalls that result from negligence, or reckless disregard or the acts or omissions on the part of SRI or any of its employees. 
  

 7 

 (g) Upon request, provide SRI with the following records for the Disposable Products:
(i) product specifications; (ii) if the Disposable Products are not manufactured directly by Cardinal Health, the name and address of the actual manufacturer of the Disposable Products and the location(s) where the Disposable Products are
manufactured; (iii) quality control specifications to include testing methods, sampling procedures, and acceptance levels; and (iv) sterilization records. To the extent that the Disposable Products are manufactured, assembled or labeled by
Cardinal Health, Cardinal Health will not make any change in the manufacture, assembly, or labeling process of the Disposable Products which could affect the quality of the Disposable Products and/or the location where Disposable Products are
manufactured without SRI’s prior written consent, which shall not be unreasonably withheld. 
 (h) Provide primary sales
support for the Disposable Products to SRI’s customers and timely respond to all requests from SRI’s customers relating to substitutions and expansions of the Disposable Products. 
 (i) Cardinal shall actively work to increase the kit size and value of SRI’s disposable accessory pack business with the SRI Legacy
Customers. 
 2.10 Purchase of SRI Disposable Products by Cardinal Health. Within sixty (60) days after the
Effective Date, Cardinal Health shall purchase from SRI all of SRI’s raw materials inventory of disposable products (other than the Disposable Products purchased by SRI pursuant to this Agreement and components that are not actively tied to SRI
Legacy Customer bills of materials on the date of such purchase) for a purchase price equal to SRI’s actual cost of such products. Notwithstanding the foregoing, Cardinal Health shall not be required to purchase any products with less than nine
(9) months left prior to their expiration. In addition, to assist SRI with the reduction of any excess raw material inventory held by SRI, Cardinal Health shall have the option to purchase from SRI any raw materials that are not tied to bills
of materials on the purchase date for an amount equal to Cardinal Health’s acquisition cost. Cardinal Health shall be responsible for all freight and other transportation charges relating to the delivery of such disposable products to Cardinal
Health or its designee. SRI represents and warrants to Cardinal Health, as of the date of such sale, that all such disposable products sold to Suppler will be of good and merchantable quality, not adulterated, and will conform to and perform in
accordance with specifications, fit for their particular purpose, and free from all defects in material and workmanship. 
 2.11
Payments to GPOs. SRI shall be responsible to continue to make any required payments to GPOs, if any, in connection with SRI Legacy Customers. For sales of the Hybrid Kits, Cardinal Health will be responsible to make payments to
GPOs, if any, with respect to the Cardinal Health Components and SRI will be responsible to make payments to GPOs, if any, with respect to the SRI Components. The terms of this Section 2.11 shall apply with respect to the Disposable Products
covered by this Section 2 as well as the Component Products covered by Section 3. 
  

 8 

	3.	COMPONENT PRODUCTS 

 3.1 Products Covered by
this Article. The products covered by this Article are the Component Products. There are no volume or purchase commitments of any kind under this Article. 
 3.2 Grant of Distributorship; Marketing and Promotion. Cardinal Health appoints SRI as the exclusive distributor of the Cardinal Health Components to the Customers in the Territory, provided such
Cardinal Health Components are only distributed as a part of the Hybrid Kits, and SRI accepts such grant for the term and on the conditions stated in this Agreement. SRI and Cardinal Health will engage in marketing and promotional activities as
specified in Exhibit A to this Agreement. The parties will share marketing and promotional expenses as follows: SRI: 70%; Cardinal Health: 30%. 
 3.3 Pricing. Cardinal Health shall provide the Cardinal Health Components to SRI in exchange for the amount otherwise payable to it pursuant to the revenue sharing arrangement set forth in
Section 3.4. No separate consideration for the Cardinal Health Components shall be payable by SRI under this Agreement. The parties shall mutually agree regarding the Hybrid Kit prices to be charged to each Customer pursuant to each Customer
Agreement, or set a mutually agreeable range for those prices. These prices might be different for each Customer, depending on market conditions and changes in the component products provided as part of the Hybrid Kit. The parties shall not add
charges of any kind without discussion with the Operating Committee, including charges for packaging, labeling, taxes, storage, insurance, boxing, crating, and shipping. For the avoidance of doubt, SRI may charge a delivery fee. 
 3.4 Revenue Sharing. Unless the parties agree otherwise in writing, for each Hybrid Kit sold to a Customer, the Non-Billing Party shall be
entitled to receive from the Billing Party a fixed margin reconciled quarterly to the actual margin in accordance with this Section 3.4 as follows: for each Hybrid Kit sold to a Customer, the Non-Billing Party shall be entitled to receive from
the Billing Party an amount equal to the product of (i) the price of the Hybrid Product (as billed to the Customer) multiplied by (ii) the quotient of (A) the aggregate cost (as approved by the Operating Committee) of the
Non-Billing Party’s component products used in such Hybrid Kit divided by the aggregate cost (as approved by the Operating Committee) of all component products used in such Hybrid Kit. For example, if the parties sell to a Customer a
Hybrid Kit having a total component cost of $100 (comprised of components of the Non-Billing Party with a cost of $70 and components of the Billing Party with a cost of $30) for a price of $200, the Non-Billing Party shall be entitled to receive
$140 from the Billing Party. For the avoidance of doubt, each party shall be responsible for all sale commissions payable to such party’s sales personnel. 
 3.5 Billing and Collection. For each Customer, the parties shall mutually determine which party shall provide billing, collection and related administrative services for such Customer (the
“Billing Party”). The Billing Party shall invoice Customers for any taxes required to be paid by the Customers. Within fifteen (15) days after the Billing Party actually receives 

  

 9 

 
payment from a Customer, the Billing Party shall pay to the other party (the “Non-Billing Party”) the amount determined in accordance with
Section 3.4, less any sales or excise taxes that the Billing Party bills, collects, and pays to taxing authorities. The Billing Party shall provide along with the payment described in this Section 3.5 a detailed listing (by Customer) of
the total amount billed for each Hybrid Kit and an itemization of Hybrid Kits purchased and component parts with respect to such bill. With respect to Customers for which Cardinal Health is the Billing Party, SRI shall transmit to Cardinal Health on
a daily basis all delivery documents and other information reasonably requested by Cardinal Health. 
 3.6 Order
Processing. For each Customer or prospective Customer, the parties shall mutually determine which party shall provide the staff it deems reasonably necessary to accept orders from such Customer, negotiate the Customer Agreement and provide
other client service support. 
 3.7 Customer Agreements. The parties shall evidence supply arrangements with the
Customers with Customer Agreements. The parties shall cooperate to develop a form Customer Agreement to use in selling the Hybrid Program, which will describe the products and services to be provided, delivery and payment arrangements, and other
terms and conditions. Each party may enter into Customer Agreements without approval by the other party, unless the Customer Agreement materially differs from the form agreement. If the Customer Agreement materially differs from the form agreement,
such alterations must be approved by both parties. Promptly after a party enters into a Customer Agreement, such party shall provide an executed copy of the Customer Agreement to the other party. 
 3.8 Customer Service. With respect to each Customer, the Billing Party shall be primarily responsible for providing collection and
related administrative services for such Customer, including receiving Customer service requests and complaints. If such requests or complaints primarily relate to the Non-Billing Party’s products or services, the Billing Party shall notify the
Non-Billing Party of such requests or complaints. Each party shall use its reasonable efforts to resolve and respond to any Customer request or complaint that is primarily related to its products or services. 
 3.9 Delivery, Risk of Loss. The Cardinal Health Components shall be held by SRI on a consignment basis. The relationship between SRI and
Cardinal Health with respect to the Cardinal Health Components shall be that of a consignor and consignee in which consignor (Cardinal Health) deposits the Cardinal Health Components with consignee (SRI) for the purpose of producing the Hybrid Kits
sold to SRI’s and Cardinal Health’s customers. Title and risk of loss shall remain with Cardinal Health until delivery to the Customer at which time title and risk of loss will pass to Customer. SRI shall be responsible for risk of loss or
damage to the Cardinal Health Components while at SRI’s facilities. Unless agreed to by SRI in advance, Cardinal Health shall not deliver any partial orders. In addition, SRI may refuse to accept, and may return to Cardinal Health, freight
collect, at Cardinal Health’s risk, any Cardinal Health Components that are not ordered by SRI. 
  

 10 

 3.10 Nonconforming Products. SRI may reject a delivery of Cardinal Health Components
up to 72 hours after delivery if such Cardinal Health Components are nonconforming. If SRI properly rejects any Cardinal Health Components as nonconforming, Cardinal Health, at its sole cost and expense, as soon as practicable after the effective
date of SRI’s notice of rejection, shall either (a) cause the rejected Cardinal Health Components to conform or (b) deliver to SRI new Cardinal Health Components that conform to the order. Cardinal Health acknowledges that Disposable
Products are also subject to acceptance or rejection by Customers, and will promptly following any Customer rejection, (i) cause the rejected Disposable Products to conform or (ii) deliver to SRI new Disposable Products that conform to the
order. 
 3.11 Inspection. With respect to those Cardinal Health Components manufactured by Cardinal Health, Cardinal
Health shall permit SRI or its agents or representatives to inspect and observe finished Cardinal Health Components in the process of manufacture, at any reasonable time during Cardinal Health’s normal business hours, and shall provide adequate
space and facilities necessary for SRI’s agents or representatives to conduct an inspection or observation upon reasonable advance notice to Cardinal Health. 
 3.12 SRI’s Duties Regarding the SRI Components and Cardinal Health Components. With respect to the Component Products and SRI Components, SRI shall: 
 (a) Submit its order for Cardinal Health Components via an electronic data interchange (EDI) or Cardinal Health’s Web-based ordering
system, such as www.Cardinal.com. 
 (b) Maintain 98% SRI Component Fill Rate (as defined below) for SRI Components.
“SRI Component Fill Rate” is defined as (i) the quantity of the SRI Components meeting the warranty requirements set forth in Section 4.1 actually delivered to the Customer as of the delivery date set forth in the Customer
Agreement (ii) divided by the quantity of SRI Components that should have been delivered by SRI to the Customer in accordance with the applicable Customer Agreement. Cardinal Health will measure the SRI Component Fill Rate on a quarterly
basis with respect to all of Hybrid Kits delivered to Customers for such calendar quarter. If SRI fails to meet the SRI Component Fill Rate with respect to any calendar quarter and, after notice of such failure by Cardinal Health, fails to maintain
the SRI Component Fill Rate for the immediately following calendar quarter, Cardinal Health may invoice and collect from SRI an amount equal to 10% of the value of the SRI Components for each 1% the SRI Component Fill Rate was below 98% with respect
to the Hybrid Kits delivered for any calendar quarter for which the SRI Component Fill Rate was below 98%. Cardinal Health acknowledges that SRI’s ability to comply with the foregoing requirements depends on its timely receipt of (A) the
Cardinal Health Components and (B) accurate and complete forecasts and ordering information from SRI via an electronic data interchange (EDI) or Cardinal Health’s Web-based ordering system, such as www.Cardinal.com. 
  

 11 

 (c) Maintain complete and accurate records for such periods as may be required by
applicable law, of all the Component Products and SRI Components sold by it as part of the Hybrid Kits. 
 (d) Notify Cardinal
Health and the appropriate federal, state and local authorities of any customer complaints or other occurrences regarding the SRI Components which are required to be so reported or that may render all or any of the SRI Components in violation of a
law or regulation, evaluating all complaints and responding to Cardinal Health in writing on the resolution of any complaints from Cardinal Health or its customers. SRI and Cardinal Health shall provide each other with any information it receives
regarding such occurrences. SRI shall be responsible for evaluating all complaints relating to the SRI Components and for responding to Cardinal Health in writing. 
 (e) In the event that any defect in a SRI Component or any regulatory or government action requires that all or part of a SRI Component be
recalled, destroyed, withheld from the market, or be subjected to a Recall, SRI shall immediately notify Cardinal Health of the same and bear the entire responsibility of the Recall, at no cost to Cardinal Health, and shall reimburse Cardinal Health
for all reasonable and direct costs associated with all Recalls, except those Recalls that result from negligence or reckless disregard or the acts or omissions on the part of Cardinal Health or any of its employees. 
 (f) Upon request, provide Cardinal Health with the following records for the SRI Components: (i) product specifications; (ii) if
the SRI Components are not manufactured directly by SRI, the name and address of the actual manufacturer of the SRI Components and the location(s) where the SRI Components are manufactured; (iii) quality control specifications to include
testing methods, sampling procedures, and acceptance levels; and (iv) sterilization records. To the extent that the SRI Components are manufactured, assembled or labeled by SRI, SRI will not make any change in the manufacture, assembly, or
labeling process of the SRI Components which could affect the quality of the SRI Components and/or the location where SRI Components are manufactured without Cardinal Health’s prior written consent, which shall not be unreasonably withheld.

 (g) Make all claims for any discrepancies in shipping, unpaid invoices, rebate requests, or any other discrepancy resulting
in receivable discrepancy in writing within one (1) year of the date of the discrepancy. Cardinal Health shall not be obligated to make payments for, or investigate claims which are dated more than one (1) year prior to SRI’s written
claim or request for investigation. 
 (h) Provide to Cardinal Health on a monthly basis, within fifteen (15) days after
the end of each month, a report showing sales of each Product to each Customer during the prior month and such other information as may be reasonably necessary for the administration of this Agreement, such as a rolling 90 day forecast. The reports
shall be provided in an electronic data interchange format agreed upon by both SRI and Cardinal Health. 
  

 12 

 (i) Provide prompt and effective customer service with regard to the SRI Components.

 (j) Comply with Cardinal Health’s then current returned goods policy. 
 3.13 Cardinal Health’s Duties Regarding Cardinal Health Components. With respect to the Cardinal Health Components, Cardinal
Health shall: 
 (a) Timely ship all Cardinal Health Components to the SRI facilities designated by SRI in the applicable
purchase order. 
 (b) Maintain 98% Component Fill Rate (as defined below) for Cardinal Health Components. “Component
Fill Rate” is defined as (i) the quantity of Component Products meeting the warranty requirements set forth in Section 4.1 actually shipped to SRI as of the delivery date set forth in SRI’s purchase order
(ii) divided by the quantity of Cardinal Health Components that should have been shipped in accordance with SRI’s purchase order. SRI will measure the Component Fill Rate on a quarterly basis with respect to all of the purchase
orders SRI submits to Cardinal Health for such calendar quarter. If Cardinal Health fails to meet the Component Fill Rate with respect to any calendar quarter and, after notice of such failure by SRI, fails to maintain the Component Fill Rate for
the immediately following calendar quarter, SRI may invoice and collect from Cardinal Health an amount equal to 10% of the value of the Cardinal Health Components for each 1% the Component Fill Rate was below 98% with respect to the purchase orders
for any calendar quarter for which the Component Fill Rate was below 98%. SRI acknowledges that Cardinal Health’s ability to comply with the foregoing requirements depends on its timely receipt of accurate and complete forecasts and ordering
via an electronic data interchange (EDI) or Cardinal Health’s Web-based ordering system, such as www.Cardinal.com. 
 (c)
Take all necessary action to comply with applicable the FDA and other federal, state and local requirements in connection with the manufacture, sale, distribution and provision of the Cardinal Health Components. These obligations include without
limitation compliance with the applicable sections of the Quality System Regulation (21 C.F.R. Part 820). Each party shall possess a Quality Assurance System that adheres to applicable laws, rules, and regulations, including without limitation the
practices and regulations of the FDA (including without limitation the applicable sections of the current Quality System Regulations as expressed in 21 C.F.R. Part 820 and Pre-Market Notification Procedures of 21 C.F.R. Part 807, Subpart E).

  

 13 

 (d) Notify SRI and the appropriate federal, state and local authorities of any customer
complaints or other occurrences regarding the Cardinal Health Components which are required to be so reported or that may render all or any of the Cardinal Health Components in violation of a law or regulation, evaluating all complaints and
responding to SRI in writing on the resolution of any complaints from SRI or its customers. SRI and Cardinal Health shall provide each other with any information it receives regarding such occurrences. Cardinal Health shall be responsible for
evaluating all complaints and for responding to SRI in writing. 
 (e) In the event that any defect in a Component or any
regulatory or government action requires that all or part of a Component be recalled, destroyed, withheld from the market, or be subjected to a Recall, Cardinal Health shall immediately notify SRI of the same and bear the entire responsibility of
the Recall, at no cost to SRI, and shall reimburse SRI for all reasonable and direct costs associated with all Recalls, except those Recalls that result from negligence or reckless disregard or the acts or omissions on the part of SRI or any of its
employees. 
 (f) Upon request, provide SRI with the following records for the Cardinal Health Components: (i) product
specifications; (ii) if the Cardinal Health Components are not manufactured directly by Cardinal Health, the name and address of the actual manufacturer of the Cardinal Health Components and the location(s) where the Cardinal Health Components
are manufactured; (iii) quality control specifications to include testing methods, sampling procedures, and acceptance levels; and (iv) sterilization records. To the extent that the Cardinal Health Components are manufactured, assembled or
labeled by Cardinal Health, Cardinal Health will not make any change in the manufacture, assembly, or labeling process of the Cardinal Health Components which could affect the quality of the Cardinal Health Components and/or the location where
Cardinal Health Components are manufactured without SRI’s prior written consent, which shall not be unreasonably withheld. 
 (g) Make all claims for any discrepancies in shipping, unpaid invoices, rebate requests, or any other discrepancy resulting in receivable discrepancy in writing within one (1) year of the date of the discrepancy. SRI shall not be
obligated to make payments for, or investigate claims which are dated more than one (1) year prior to Cardinal Health’s written claim or request for investigation. 
 (h) Within five business days after the end of each month and receipt of customer purchase data from SRI, pay to SRI (i) a delivery
fee in the amount that SRI negotiates with the Customers, but only when Cardinal Health is billing and collecting from the customers, (ii) with respect to each Customer for which SRI is the Billing Party, a tracing fee of [* * *]% of Cardinal
Health’s gross revenues with respect to the Cardinal Health Components, plus a prompt payment fee of [* * *]% 15, net 45 and (iii) [* * *]% of gross revenues from the Cardinal Health Components as a marketing fee. 
  

 14 

 3.14 Cash Incentive. To assist SRI in funding marketing and transition expenses,
including but not limited to, the opening of depots in the territories not served by SRI at the date of this Agreement, the hiring of one sales vice president, eight account executives and other sales and marketing personnel to support the Hybrid
Program, the cost of closing the disposable assembly plant, the cost of development of new marketing collateral and advertising, and the cost to purchase and implement EDI applications to support the requirements under the Agreement, Cardinal Health
shall pay to SRI the amount of $1,250,000 in cash, payable $1,000,000 on January 2, 2009, and $250,000 on January 4, 2010. 
 3.15 Other Obligations. Cardinal and SRI shall evaluate opportunities to capitalize on the SRI operating room delivery expertise in the following areas: (a) delivery of other Cardinal Health products and
(b) inclusion of instrument and instrument processing as an adjunct to the Cardinal Health PBDS program. Further, Cardinal Health and SRI shall use reasonable efforts to create benefit to SRI from the Cardinal/Presource’s national group
purchasing organization relationships. 
  

	4.	WARRANTIES AND INDEMNIFICATION 

 4.1
Warranties. The parties will be providing products that constitute separate components of the Hybrid Kits. Each party desires to clearly identify its warranty responsibilities for its products and to indemnify the other party for
liabilities that arise from its products used by the Customers. These warranties and covenants are intended solely for the benefit of the other party. Nothing in this section expands a party’s warranty or indemnity responsibility to the
Customers or any other person not a party to this Agreement. 
 Each party warrants and represents to the other party as of the Effective
Date and for the term of this Agreement, as follows: 
 (a) It has full authority to enter into this Agreement and carry out
its obligations under this Agreement, and further that this Agreement is not inconsistent with and will not violate any contractual arrangement or other legal obligation of the party. 
 (b) It has the legally enforceable right to use all technology associated with its products and services, whether patented or unpatented,
and that the use of this technology does not violate any agreement, instrument or understanding, oral or written, to which it is a party. 
 (c) It is the sole and exclusive owner of its products and services, and those products and services do not incorporate or infringe upon any copyright, patent, trademark, service mark, trade name, idea, process,
know-how, development, invention, technology, or any other form of intellectual property (collectively “Intellectual Property”) that it does not own or license. 
 (d) Its disposable products, if any, delivered to the Customers pursuant to this Agreement will be of good, and merchantable quality, not
adulterated, and will conform to and perform in accordance with specifications, fit for their particular purpose, and free from all defects in material and workmanship. 
  

 15 

 (e) Its reusable products, if any, will be of good quality and will conform to and
perform the functions intended for them. 
 (f) Its products delivered to the Customers pursuant to this Agreement will be
manufactured in compliance with applicable local, state and federal laws and regulations, including without limitation those of the FDA, and have all applicable 510(k) and other approvals. 
 (g) Its services under this Agreement will be performed with the standards of care, skill, and diligence normally provided by
professionals or experts in the performance of those services or similar services and in a lawful manner and in compliance with applicable federal, state and local laws and regulations including without limitation those of the FDA. 
 (h) Its conduct will preserve, protect, enhance, and maintain the trade, business, and goodwill of the other party and not be inimical or
in any way contrary to the best interests of the other party. 
 (i) Its warranty does not apply to any nonconformity or
defect caused by (i) operation of any product in excess of its rated or specified limits or capabilities; (ii) misuse, abuse or negligent operation; or (iii) unauthorized product modification. 
 These warranties address current and future performance and apply for as long as the applicable products are in use. Disclaimers of any other express or
implied warranties contained in or arising under this Agreement or otherwise will not be deemed to be a disclaimer of this warranty. 
 Each
party shall promptly notify the other party of any of its violations of the foregoing warranties of which it has knowledge or which are asserted by a Customer or a third party. 
 The representations and warranties set forth in this Section 4.1 are the sole and exclusive representations and warranties made by each party to the
other and neither party makes any other representations, warranties or guarantees, including any implied warranties, of any kind whatsoever. 
 4.2 Indemnification. 
 (a) Generally. Each party shall indemnify the other party, its
successors and permitted assigns, and any of its officers, directors, employees, representatives, and/or agents, and hold them harmless from all costs, loss, claims, damage, expense, liabilities, and judgments (including premiums for bonds, fees for
experts and investigators, and all legal fees, costs, and expenses incurred before a lawsuit is filed in regulatory or trial, 

  

 16 

 
appellate, bankruptcy and judgment execution proceeding) incurred by the other party because of the indemnifying party’s breach of warranty, failure to
comply with this Agreement, willful misconduct, or negligent acts or omissions. Notwithstanding the foregoing, SRI’s indemnity obligations in this Agreement shall also flow to Cardinal Health’s parent company, Cardinal Health, Inc.

 (b) Infringement Indemnification. Should any aspect of a party’s products and services become the
subject of an Intellectual Property infringement claim, action, or proceeding, the party shall, at its expense and the other party’s option, (i) obtain a license that would permit the other party and all affected Customers to exercise
those rights granted to them under this Agreement or under Customer Agreements, as the case may be, or (ii) modify the allegedly infringing products to render them non-infringing. In addition, the claimed Intellectual Property infringement will
be a claim subject to indemnification under Section 4.2(a). 
 (c) Product Liability and Other Damage Indemnity.
The claims subject to indemnity under Section 4.2(a) will include (i) a defect or alleged defect in the products and services provided by the indemnifying party under a Customer Agreement, including without limitation defects relating to
manufacturing, improper testing, design, quality of service, or any breach of warranty regarding the products and services or any component of them, (ii) misrepresentations made by the indemnifying party in connection with the promotion,
marketing, sale, distribution, use, safety, or efficacy of the products and services based upon information supplied by the indemnifying party, (iii) the content of any labeling, inserts, instruction manuals, or Advertising supplied or compiled
by the indemnifying party, or (iv) any Recall taken with respect to an indemnifying party’s products and services. 
 4.3
Liability Limitation. Each party acknowledges and agrees that the other party shall not be responsible for any indirect, incidental, consequential or special damages of any kind (including without limitation loss of profits or loss of use)
arising from the sale or other distribution of products and services that the party does not originate, whether asserted in contract, tort (including negligence and strict product liability), or otherwise. Neither party will be responsible for loss
of or damage to the other party’s products following delivery to the Customer. 
  

	5.	INSURANCE 

 Commencing with the Effective Date and
until the expiration of the most remote statute of limitations for any claim that might arise under this Agreement, each party shall maintain at its own expense comprehensive general liability insurance for bodily injury, death and/or property
damage (including coverages for product liability, completed operations, contractual liability and personal injury liability) in the amount of Two Million Dollars ($2,000,000) for any damages resulting from its acts or omissions, or its
employees or agents under this Agreement. In addition, each party shall maintain during this same period Workers’ Compensation insurance 

  

 17 

 
in such amount(s) that are required by law, together with automobile liability insurance with minimum coverages of $1,000,000. The parties shall cause these
policies to name the other party as an additional insured. Each party shall furnish to the other party certificates or other evidence of these policies on execution of this Agreement endeavor to provide the other party with thirty
(30) days’ prior written notice of any termination or cancellation of any of these policies. Both parties acknowledge that Cardinal Health may self-insure all or a portion of the above requirements. 
  

	6.	REGULATORY MATTERS 

 6.1 Regulatory
Compliance. Each party shall take all necessary action to comply with applicable FDA and other federal, state and local requirements in connection with the manufacture, sale, distribution and provision of its products and its furnishing of
services under this Agreement. These obligations include without limitation compliance with the applicable sections of the Quality System Regulation (21 C.F.R. Part 820). Each party shall possess a Quality Assurance System that adheres to applicable
laws, rules, and regulations, including without limitation the practices and regulations of the FDA (including without limitation the applicable sections of the current Quality System Regulations as expressed in 21 C.F.R. Part 820 and Pre-Market
Notification Procedures of 21 C.F.R. Part 807, Subpart E). 
 6.2 Notification of Defects. Each party shall promptly
notify the other party via telecopy and in writing should it become aware, through a Customer complaint or otherwise, of any defect or condition which may render all or any component part of the Hybrid Program in violation of a law or regulation.

 6.3 Recalls and Field Corrective Actions. In the event that any defect in a Hybrid Kit or any regulatory or
government action requires that all or part of the Hybrid Kit be subjected to a Recall, the party that originated the affected product or service shall immediately notify the other party of the same and bear the entire responsibility of the Recall,
at no cost to the other party. The other party shall reasonably assist the originating party in carrying out the Recall at the originating party’s request, cost, and expense. 
 6.4 Complaints. Each party shall forward complaints regarding the Hybrid Program to the other party. The party originating the
applicable product shall conduct a complete and documented investigation and shall fully resolve such complaints in accordance with the requirements for complaint handling as promulgated by the FDA in the then current published Quality System
Requirements (21 C.F.R. Part 820) or any other applicable law, rule, or regulation. Each party shall make reasonable efforts to assure that its complaint investigations are performed and completed promptly within ninety (90) days from its
receipt of the complaint, and to the extent that a party will not complete its investigation within that time period, the party shall furnish a written explanation of the delay to the other party. If as a result of an investigation, a change in a
Hybrid Kit is necessary, the responsible party shall perform, document, and validate the change and provide the information to the other party at no charge. Each party shall notify the other party immediately of any claims that it receives of
defects in its 

  

 18 

 
products or services that constitute part of the Hybrid Kit. If a party is presented with a possible Medical Device Report (“MDR”) event
involving the provision of or failure to provide a component of a Hybrid Kit, the party originating the applicable product shall bear the responsibility for evaluation and, if necessary, submission of all information required under the applicable
MDR Regulation, as set forth in 21 C.F.R. Part 803. Prior to any such submission, the responsible party shall provide the other party with a complete copy of the MDR and any other information to be submitted by responsible party to the FDA, for the
other party’s review and approval. 
 6.5 Audits. Each party shall have the right (at its own expense) to perform a
commercially reasonable audit of the other party’s compliance with applicable FDA rules and regulations (including without limitation the applicable sections of the then-current published Quality System Requirements (21 C.F.R. Part 820) and MDR
Regulations (21 C.F.R. Part 803)) and any other applicable laws, rules, and/or regulations with respect to a Hybrid Kit and associated services during normal business hours, with reasonable prior written notice to the applicable party and subject to
Section 8. At a minimum, (i) the party’s facility being audited must be operational during the audit, (ii) the auditing party must receive access to the batch history records and sterilization records of audited party’s
products and services used in the Hybrid Kit, and (iii) the auditing party must be permitted to conduct audits of the other party which comply with the applicable sections of the then-current published Quality System Requirements (21 C.F.R.
Part 820) and any other applicable laws, rules, and regulations. The parties shall cooperate with each other to arrange such visits at mutually convenient times. In addition, a party’s personnel may periodically travel to the other party’s
facilities to observe testing and validation activities, receive information with respect thereto (subject to Section 8), and ensure that products and services are being tested in accordance with established practices. 
  

	7.	TERM AND TERMINATION 

 7.1
Term. This Agreement will be for an initial term of five (5) years or until earlier terminated by a party in accordance with this section, provided that all rights and obligations accrued by the expiration or termination date will
survive the expiration or termination of this Agreement. The term shall renew for successive one (1) year terms thereafter unless either party provides notice of non-renewal at least one hundred twenty (120) days prior to the expiration of
the then current term. 
 7.2 Termination. 
 (a) This Agreement may be terminated by either party immediately on notice if: 
 (i) The other party fails to make payments when due to the terminating party within 10 days after written notice or neglects or fails to
perform or observe any of its other material obligations under this Agreement (including recurring quality or service problems), unless the condition is remedied within 30 days after written notice has been given to the party. 
  

 19 

 (ii) The other party makes an assignment for the benefit of creditors or a petition under
the Bankruptcy Code is filed by or against the other party (if an involuntary petition, the petition is not dismissed within 60 days after it is filed) or a receiver is appointed for the business of the other party. 
 (iii) The other party ceases doing business as a going concern or attempts to transfer or assign this Agreement in a manner that is not
permitted. 
 (iv) The other party or its officer commits any acts that are dishonest or fraudulent with respect to the
parties’ relationship under this Agreement or that materially adversely affects the ability to perform of the terminating party. The terminating party shall give 30 days’ advance notice of any condition that materially adversely affects
the other party’s ability to perform. 
 (b) This Agreement may be terminated by SRI immediately on notice if a Change of
Control occurs. 
 7.3 Effect of Termination. Upon expiration or earlier termination of this Agreement, no party shall
have any further responsibilities or obligations to the other party, except for its obligations under Sections 4 and 8 and as follows: 
 (a) With respect to SRI Legacy Customers for which SRI is the Billing Party as of the expiration or earlier termination of this Agreement, (i) Cardinal Health shall continue to supply the Cardinal Health
Components to SRI in accordance with this Agreement until the expiration or earlier termination of the applicable Customer Agreements, (ii) neither Cardinal Health nor its affiliates shall offer or sell any Competing Products to such Customers
for a period of twelve (12) months after the expiration or earlier termination of the applicable Customer Agreements and (iii) after the expiration or earlier termination of the applicable Customer Agreements, SRI shall have the option to
replace Cardinal Health as the supplier of the disposable component products used in the Hybrid Kits for such Customer. 
 (b)
With respect to SRI Legacy Customers for which Cardinal Health is the Billing Party as of the expiration or earlier termination of this Agreement, (i) Cardinal Health shall cooperate with SRI to transition the billing, collection and related
administrative services for such Customers from Cardinal Health to SRI, (ii) Cardinal Health shall continue to supply the Cardinal Health Components to SRI in accordance with this Agreement until the expiration or earlier termination of the
applicable Customer Agreements, (iii) neither Cardinal Health nor its affiliates shall offer or sell any Competing Products to such Customers for a period of twelve (12) months after the expiration or earlier termination of the applicable
Customer Agreements, (iv) after the 

  

 20 

 
expiration or earlier termination of the applicable Customer Agreements, SRI shall have the option to replace Cardinal Health as the supplier of the
disposable component products used in the Hybrid Kits for such Customer. 
 (c) With respect to Customers other than SRI
Legacy Customers for which Cardinal Health is the Billing Party as of the expiration or earlier termination of this Agreement, (i) the parties shall cooperate to separate the billing, collection and related administrative services for such
Customers according to Cardinal Health Components and SRI Components and SRI Services, (ii) neither SRI nor its affiliates shall offer or sell to such Customers any disposable products for a period of twelve (12) months after the
expiration or earlier termination of the applicable Customer Agreements, and (iii) Cardinal Health shall not offer or sell any Competing Products to such Customers for a period of twelve (12) months after the expiration or earlier
termination of the applicable Customer Agreements. 
 (d) With respect to Customers other than SRI Legacy Customers for which
SRI is the Billing Party as of the expiration or earlier termination of this Agreement, (i) the parties shall cooperate to separate the billing, collection and related administrative services for such Customers according to Cardinal Health
Components and SRI Components and SRI Services, and (ii) neither SRI nor its affiliates shall offer or sell to such Customers any disposable products for a period of twelve (12) months after the expiration or earlier termination of the
applicable Customer Agreements, and (iii) neither Cardinal Health nor its affiliates shall offer or sell any Competing Products to such Customers for a period of twelve (12) months after the expiration or earlier termination of the
applicable Customer Agreements. 
 (e) With respect to Cardinal Health Presource/Convertors Legacy Customers for which
Cardinal Health is the Billing Party as of the expiration or earlier termination of this Agreement, (i) SRI shall continue to supply the SRI Components and SRI Services to Cardinal Health Presource/Convertors Legacy Customers in accordance with
this Agreement until the expiration or earlier termination of the applicable Customer Agreements, (ii) neither SRI nor its affiliates shall offer or sell any Competing Products to such Customers for a period of twelve (12) months after the
expiration or earlier termination of the applicable Customer Agreements and (iii) after the expiration or earlier termination of the applicable Customer Agreements, Cardinal Health shall have the option to replace SRI as the supplier of the SRI
Component products and SRI Services used in the Hybrid Kits for such Customer. 
 (f) In the event SRI terminates this
Agreement pursuant to Section 7.2(b), SRI shall, within five (5) business days of termination of this Agreement, pay to Cardinal Health a termination fee in the amount of one million two hundred and fifty thousand dollars $1,250,000) (the
“Termination Fee”) if termination occurs during the first twelve (12) months after the Effective Date, and if termination occurs more than twelve (12) months after the Effective Date, the Termination Fee shall be prorated
in equal amounts 

  

 21 

 
over the remaining 48 months (for example, if the Agreement is terminated in the 36th month after the Effective Date, SRI shall pay to Cardinal Health a Termination Fee in the amount of $625,000). Except as set forth in this Section 7.3, upon payment of the Termination Fee pursuant to this
Section 7.3 (f), SRI shall have no further liability to Cardinal Health with respect to this Agreement or the transactions contemplated by this Agreement. 
 Notwithstanding anything to the contrary set forth above, the terminating party shall have the option at any time after the expiration or earlier termination of this Agreement to replace the other party as the
supplier of the disposable or reusable component products used in the Hybrid Kits, if the other party fails to perform its obligations to supply its component parts to the Customers as required above. 
  

	8.	CONFIDENTIALITY; PUBLICITY 

 8.1
Restricted Information. During the term of this Agreement, the parties might furnish or make available to the other party proprietary or confidential information regarding their businesses and affairs, including without limitation
confidential information pertaining to their products, services, customers, technology, and business operations that is designated by name, trademark, or other appropriate text to be proprietary or confidential in nature (“Restricted
Information”). All Restricted Information furnished or made available to the other party during the term of this Agreement, however and whenever acquired during the term hereof, shall remain the property of the party furnishing the
information. Each party shall treat the Restricted Information as strictly confidential, shall use it solely for the purposes contemplated by this Agreement, and shall not reveal, divulge, disclose, or duplicate any Restricted Information without
the other party’s written consent, except for the party’s employees who need to know the information for purposes of carrying out the purposes of this Agreement. However, the party receiving the Restricted Information shall direct its
employees who have access to the Restricted Information to treat it as strictly confidential, and shall indemnify the other party and hold it harmless from, any damage resulting from a breach of confidentiality caused by any of its employees. Each
party shall return to the other party at the expiration of this Agreement, all Restricted Information that it received from the other party. Each party’s specifications for its products and services are its exclusive property. The
confidentiality restrictions defined in this paragraph shall remain in effect for twenty (24) months beyond termination of the Agreement. 
 8.2 Confidential Terms of this Agreement. Each party shall treat the Margin Percentages contemplated by Section 2.3 of this Agreement and the fee amounts in Section 2.9(b) and 3.13(h) as strictly confidential
and shall not disclose such information to any third party, except as required by applicable law or by any governmental agency. 
 8.3
Publicity. Neither party will make any press release or other public announcement regarding this Agreement without the other party’s express prior written consent, except as required under applicable law or by any governmental
agency, in which case the party required to make the press release or public disclosure shall use commercially reasonable efforts to obtain the approval of the other party as to the form, nature and extent of the press release or public announcement
prior to issuing the press release or making the public announcement. 
  

 22 

	9.	MISCELLANEOUS 

 9.1 Relationship of the
Parties. Neither party to this Agreement is an agent, partner, or legal representative of the other for any purpose, and neither party is authorized to assume or create, in writing or otherwise, an obligation of any kind in the name
or on behalf of the other party. This Agreement is not to be construed to create a financial interest in the other party’s business or to constitute a partnership or joint venture between the parties. This Agreement is for the benefit of its
parties only, and no third party is a beneficiary of it. 
 9.2 Management Committee. The parties shall establish a
management committee (the “Management Committee”) to oversee the strategic marketing relationship relating to the Hybrid Program that may arise during the term of this Agreement. The Management Committee shall consist of the senior
executive of each party and one other executive from each party. The Management Committee shall meet (via telephone or otherwise) frequently and upon request to discuss the progress, results, and resolve any conflicts of the Hybrid Program.

 9.3 Operating Committee. The parties shall establish an operating committee (the “Operating
Committee”) to handle any day-to-day matters relating to the Hybrid Program that may arise during the term of this Agreement, including without limitation the determination of (i) each Hybrid Kit price for each Customer (which shall be
determined on a Customer-by-Customer basis) and (ii) costs of Cardinal Health Components and SRI Components for purposes of the parties’ revenue sharing arrangement pursuant to Section 3.4. The Operating Committee shall consist of one
Vice President of Sales (or equivalent member of senior management) and one added marketing executive appointed by each party. The Operating Committee shall meet (via telephone or otherwise) frequently and upon request to discuss the day-to-day
operations and resolve any conflicts of the Hybrid Program. 
 9.4 Record-Keeping and Audit. Each of SRI and Cardinal
Health shall maintain complete and accurate records in such detail, form and scope as is consistent with good business practice to support and document all of the party’s financial (including cost), purchase and delivery information reasonably
required to calculate amounts payable under Section 2.3 and Section 3.4 of this Agreement. Each party shall have the right to review and audit the books and records of the other party for the purpose of verifying the accrual and payment of
any amounts payable under this Agreement. If either party desires to exercise any such audit right, then such party (the “Auditing Party”) shall furnish the other party (the “Audited Party”) with ten business
days’ prior written notice thereof. The Auditing Party shall advise in writing the Audited Party of the results of the audit. If the Auditing Party determines that it has been underpaid, the Management Committee shall work to determine whether
or not additional payment is appropriate. If the parties are unable to agree as to whether or not additional payment is appropriate within 30 days after the Auditing Party has advised the Audited Party of the results of the audit, either party may
submit the matter to arbitration in accordance with the provisions 

  

 23 

 
of Section 9.5. Each party shall be limited to one audit per calendar year and to one additional audit at any time within the two-year period following
the expiration or earlier termination of the term of this Agreement. 
 9.5 Arbitration. If any dispute between the
parties arises under this Agreement, the parties shall use reasonable efforts to settle the dispute for at least 30 days. After that period, the dispute may be submitted for arbitration, and the arbitration will be conducted before an arbitration
panel in accordance with the rules established by the American Arbitration Association. The arbitrator panel will consist of three arbitrators, with one arbitrator selected by SRI, the second arbitrator selected by Cardinal Health, and the third
arbitrator selected by agreement of the first two arbitrators. Every arbitrator must be independent (not an officer, director, employee, affiliate, or shareholder of party) without any economic or financial interest of any kind in the outcome of the
arbitration or in Cardinal Health, SRI, or any of their affiliates. The arbitration hearing will be held on such dates and at such times as the arbitration panel designates on 30 calendar days’ advance notice to the parties. Both SRI and
Cardinal Health agree that should SRI initiate the arbitration proceeding, it shall be located in Columbus, Ohio, and should Cardinal Health initiate the arbitration proceeding, it shall be located in Tampa, Florida. The decision of the arbitration
panel will be binding and conclusive as to Cardinal Health and SRI, and on the pleading of any party, any court having jurisdiction may enter a judgment of any award rendered in arbitration, which may include an award of damages. 
 9.6 SRI Trademarks. To the extent reasonably required for Cardinal Health to
perform its obligations under this Agreement, SRI grants to Cardinal Health a nonexclusive, nontransferable, nonassignable license during the term of this Agreement to use SRI’s logos, copyrights, tradenames, servicemarks and trademarks (the
“SRI Marks”). The parties acknowledge and agree that the trademark “Hybrid Preference PackTM” (the “Hybrid
Mark”) shall constitute a SRI Mark, SRI shall be the sole owner of the Hybrid Mark and SRI shall be entitled to take any actions (including making any filings) to perfect and protect SRI’s rights and interest in and to the Hybrid Mark;
provided, however, SRI shall use the Hybrid Mark exclusively in connection with the Hybrid Program and the transactions contemplated by this Agreement and shall not license the Hybrid Mark to any third party. Cardinal Health shall use
the SRI Marks only in the form and manner specified or approved by SRI in writing. Cardinal Health shall not alter, modify, dilute, or otherwise misuse the SRI Marks, and will do nothing inconsistent with SRI’s ownership of the SRI Marks.
Nothing in this Agreement conveys to Cardinal Health any right, title or interest in or to any SRI Mark, other than an express right to permissively use them solely for purposes of Cardinal Health’s performance of its obligations under this
Agreement. Cardinal Health shall submit to SRI all materials and documentation that it compiles that incorporates all or part of the SRI Marks, including any and all advertising, for review and approval. When reasonably requested by SRI, Cardinal
Health shall provide SRI with copies of materials and documentation compiled by Cardinal Health that incorporate all or part of the SRI Marks for the purpose of monitoring Cardinal Health’s compliance with the terms of this Agreement. Cardinal
Health shall not use the SRI Marks in any manner that, directly or indirectly, detracts from their value and reputation. 
  

 24 

 9.7 Cardinal Health Trademarks. To the extent reasonably required for SRI to perform
its obligations under this Agreement, Cardinal Health grants to SRI a nonexclusive, nontransferable, nonassignable license during the term of this Agreement to use Cardinal Health’s logos, copyrights, tradenames, servicemarks and trademarks
(the “Cardinal Health Marks”). SRI shall use the Cardinal Health Marks only in the form and manner specified or approved by Cardinal Health in writing. SRI shall not alter, modify, dilute, or otherwise misuse the Cardinal Health
Marks, and will do nothing inconsistent with Cardinal Health’s ownership of the Cardinal Health Marks. Nothing in this Agreement conveys to SRI any right, title or interest in or to any Cardinal Health Mark, other than an express right to
permissively use them solely for purposes of SRI’s performance of its obligations under this Agreement. SRI shall submit to Cardinal Health all materials and documentation that it compiles that incorporates all or part of the Cardinal Health
Marks, including any and all advertising, for review and approval. When reasonably requested by Cardinal Health, SRI shall provide Cardinal Health with copies of materials and documentation compiled by SRI that incorporate all or part of the
Cardinal Health Marks for the purpose of monitoring SRI’s compliance with the terms of this Agreement. SRI shall not use the Cardinal Health Marks in any manner that, directly or indirectly, detracts from their value and reputation. 

9.8 Ownership. The logos, copyrights, tradenames, servicemarks and trademarks related to (i) Cardinal Health Components are
and will remain the sole property of Cardinal Health and (ii) SRI Components and SRI Services are and will remain the sole property of SRI. 
 9.9 Rights on Termination/Expiration. On termination or expiration of this Agreement, neither party shall further use the logos, copyrights, tradenames, servicemarks and trademarks of the other party for any purpose, or
employ or use any logo, copyright, tradename, servicemark or trademark that suggests an existing relationship between the parties, or that is likely to cause confusion with the logos, copyrights, tradenames, servicemarks or trademarks of the other
party. 
 9.10 Execution. The parties may execute this Agreement in counterparts. Each executed counterpart to
this Agreement shall constitute an original document, and all executed counterparts, together, shall constitute the same agreement. 
 9.11 Notices. Except for oral requests and notices expressly authorized by this agreement, every notice, request, demand, consent, approval, and other communication required or permitted under this agreement will
be valid only if it is given in writing (or sent by telecopy and promptly confirmed in writing), conspicuously marked FOR IMMEDIATE ATTENTION, and addressed by the sender to the appropriate party at the address provided in the first paragraph of
this Agreement and to the person’s attention set forth below: 
  

	 	(a)	If to Cardinal Health: 

 Cardinal Health 200, Inc., Supply
Chain Services - Medical 
 7000 Cardinal Place 
  

 25 

 Dublin, OH 43017 
 Attn: President PreSource Products and Services 
 Facsimile: 614-652-8149 
 With copies to: 
 Cardinal Health 200, Inc.,
Supply Chain Services - Medical 
 7000 Cardinal Place 
 Dublin, OH 43017 
 Attn: General Counsel 
 Facsimile: (614) 757-6448 
  

	 	(b)	If to SRI: 

 SRI/Surgical Express, Inc. 
 12425 Race Track Road 
 Tampa, Florida 33626

 Attention: Chief Executive Officer 
 Facsimile: (813) 818-9076 
 With copies to: 
 Hill Ward Henderson PA 
 101 East Kennedy Blvd., Suite 3700 
 Tampa, Florida 33602 
 Attention: David S.
Felman, Esq. 
 Facsimile: (813) 221-2900 
 or to such other address as a party designates by notice to the other party. A validly given notice, request, demand, consent, approval, or other communication will be effective on its receipt. 
 9.12 Assignment; Subcontracting. This Agreement is not assignable by either party without the other party’s consent, which it
may withhold at its sole discretion, and any unapproved assignment will be invalid and ineffective against the other party, except that, if a party sells, merges, or exchanges all or substantially all of its assets or outstanding stock, the party
may assign this Agreement without the other party’s written consent, so long as (a) the acquiring entity executes an agreement agreeing to be bound by this Agreement, and (b) the other party reasonably and in good faith believes the
acquiring entity will perform all of the predecessor’s material obligations under this Agreement with similar diligence, responsibility, and capability. Neither party may subcontract any of its responsibilities under this Agreement to another
person without the other party’s prior approval. 
  

 26 

 9.13 Force Majeure. Neither party shall be responsible for any delay, failure, or omission
due to any cause that is beyond its reasonable control, is not due to its own negligence, and cannot be overcome with the exercise of due diligence, including, without limitation, war, riots, fires, floods, storms, lightning, epidemics, earthquakes,
hostilities, labor disturbances, expropriation or confiscation of properties, interference by civil or military authorities, or acts of God. 
 9.14 Governing Law. The validity, interpretation, construction and enforcement of this Agreement are governed by the laws of the State of New York, excluding the laws of that State pertaining to the resolution of conflicts
with laws of other jurisdictions. 
 9.15 Miscellaneous. Time is of the essence in this Agreement. This Agreement is
binding on and inures to the benefit of, the respective assignees and the successors of each party, and all references to a party in this Agreement includes its permitted assignees or successors. A delay, omission or course of dealing on the part of
a party in exercising any right, power or remedy under this Agreement will not operate as a waiver of it and a single or partial exercise of any right, waiver or remedy under this Agreement does not preclude any further exercise of it or the
exercise of any other right, power or remedy. A waiver, amendment, or modification of this Agreement would be valid and effective only if it is in writing and signed by both parties. This Agreement and the Schedules record the final, complete and
exclusive understanding of the parties to it with respect to the transactions contemplated by this Agreement and supersede any prior or contemporaneous agreement, understanding or representation, oral or written, by either of them. 
 [SIGNATURE PAGES FOLLOW] 
  

 27 

 IN WITNESS WHEREOF, the parties have duly executed this Agreement as of the Effective Date. 

 

					
	SRI/SURGICAL EXPRESS, INC.
		
	By:	 	/s/ Gerald Woodard
		 	Name:	 	Gerald Woodard
		 	Title:	 	CEO

  

					
	 CARDINAL HEALTH 200, INC.
 (through
and for its Presource business unit)

		
	By:	 	/s/ Steve Inacker
		 	Name:	 	Steve Inacker
		 	Title:	 	President/GM

 ANNEX A 
 Co-Branded Label 
 To be agreed and attached post-execution. 

 EXHIBIT A 
 1. Promotion 
 a. SRI may promote the Hybrid Kits in any fashion or media
desired to include collateral material, the SRI WEB site, advertising, etc., provided the promotion does not convey a perceived/implied endorsement of or bias for reusable drape and gown products over Convertors disposables by Presource. 

b. Subject to Section 9.7 of the Agreement, SRI may identify Cardinal Health as our channel partner in our promotion materials and
may use the Cardinal Health logo in doing so. Cardinal Health must approve the use of the Cardinal Health logo and channel partner designation. 
 c. SRI may invite Cardinal Health staff to participate in its trade show properties as part of the Cardinal Health channel partner program, provided Convertors is not a participant at the same show. 
 d. SRI may identify the channel partner relationship with Cardinal Presource in its marketing communications material used in its booth
properties. 
 e. The parties will share marketing and promotional expenses as follows: SRI: 70%; Cardinal Health: 30%.

 2. Sales Activities 
 a. The Cardinal/Presource sales force may work with the SRI sales force in the following ways: 
 (i) Cardinal Presource will share its sales and marketing roster information to include email addresses with SRI for the purposes of communicating with these individuals to facilitate the implementation of the relationship. SRI may use
these email addresses for the purpose of communicating with the Cardinal Presource sales force regarding sales opportunities for the Hybrid Kit. Any SRI produced sales and marketing promotion materials (with approved use of Cardinal Health channel
partner and logo designation) for the Hybrid Kit shall be distributed and communicated through the Cardinal Presource marketing organization unless otherwise agreed upon in advance. 
 (ii) Coordinate and hold joint calls with customers to introduce, explain, and present the Hybrid Kit concept. 
 (iii) Coordinate and hold joint calls to present customer requested Hybrid Kit quotations/proposals and RFP responses. 
 (iv) Arrange meetings of the SRI’s sales and marketing staff with the Cardinal/Presource training group for the purpose of
acquainting them with concepts and elements of the reusable components of the Hybrid Kit offering. 

 (v) Arrange SRI plant tours for Cardinal/Presource sales and marketing staff to prepare
for prospective customer tours. 
 (vi) Arrange joint meetings with customers who have purchased the Hybrid Kit or who are SRI
Legacy Customers and therefore are now dependent upon their disposable support coming from Cardinal/Presource. 
 (vii)
Cardinal/Presource and SRI will mutually share leads and customer initiated interest in the Hybrid Kit concept. 
 3. Quotations and
RFP responses 
 a. Cardinal/Presource staff will support SRI staff (including the sales forces) in configuring and
pricing the Hybrid Kit quotations/proposals and RFP responses. 
 b. All Hybrid Kit quotations/proposals and RFP responses
must be approved by duly authorized representatives of both parties prior to presentation or transmittal to a prospective customer. 
 c. SRI will construct and package the Hybrid Kit quotations/proposals and RFP responses. 
 d. SRI will provide
copies of these Hybrid Kit quotations/proposals and RFP responses to Cardinal Presource. 
 e. The SRI quotation/proposal and
RFP response package may reference the channel partner relationship and may contain use of the Cardinal Health logo as appropriate. 
 4.
Customer Initiated Interest 
 In the event a Cardinal Presource/Convertors Legacy Customer expresses an interest in a Hybrid
Kit solution, Cardinal/Presource will be free to work with SRI to engage that customer. This applies to all customers including those belonging to the GPO’s or under an existing government contract. 
 5. GPO and Government promotion 
 SRI may promote the Hybrid Kit with Cardinal Presource as its channel partner to all GPO’s and government entities. Any GPO contracting arrangements for the Hybrid Program must be approved by both parties prior to any official
contractual arrangements. 
  

 31

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00155-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00155-of-00352.parquet"}]]